
Opinion|Videos|December 15, 2023
Adapting MDS Treatment Approach
Key opinion leaders discuss the process of adapting MDS treatment strategies for optimal impact of care.
Advertisement
Episodes in this series

Advertisement
Related to this article

Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.

GRADE meta-analysis: hepatitis A vaccine blocks 96% in pre-exposure vaccination; outbreak response uses millions of doses, but post-exposure prophylaxis evidence is weak.

Alcohol abuse was the strongest post-trauma psychiatric predictor of cardiovascular events, with mood disorders more prominent among women.

Individuals with or at risk for arrhythmogenic cardiomyopathy had no added risk of ventricular arrhythmia from strength training, unlike endurance exercise.

A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.

Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.

Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
Advertisement
Advertisement
Trending on AJMC
1
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
4
Across the US, Obesity Care Still Lacks an Owner
5

